Abstract:2934 Breast cancer presents as estrogen receptor alpha (ERα) positive or negative. ERα- tumors have a poor prognosis, are resistant to hormonal therapies, and frequently show overexpression, amplification, and/or hyperactivation of growth factor receptors, such as the erbB family. Using cell line models that mimic this elevated growth factor signaling by EGFR and erbB-2 in MCF-7 breast cancer cells, we have previously shown that hyperactivation of downstream p42/44 MAPK results in the reversible loss of ERα expression, and that in addition to the direct effect of MAPK on ERα, indirect activation of NFkB by MAPK also plays a role. In this study, we set out to determine if the inihibition of MAPK activity in established ERα- breast cancer cell lines could restore ERα expression and further, if this re-expressed ERα could now restore anti-estrogen response. MAPK inhibition via treatment with U0126 in 3 ERα- breast cancer cell lines, the EGFR overexpressing SUM 229s, the EGFR/c-erbB-2 dual overexperssing SUM 190s, and the RhoC overexpressing SUM 149s resulted in the sustained re-expression of ERα protein in all 3 cell lines. To ascertain that this re-expressed ERα could now restore anti-estrogen sensitivity, growth assays analyzing the effects of 4-hydroxy-tamoxifen (4HT) and the pure antiestrogen ICI 182,780 (faslodex) at 10-7 M alone, 5 μM U0126 alone, or the combination of 4HT or ICI and U0126 on cell proliferation were performed by WST-1 assay. ERα- SUM 229 and 149 cells were resistant to both 4HT and ICI. While having no growth inhibitory effects on its own, 5 μM U016 restored the growth inhibitory effects of both 4HT and ICI in ERα- SUM 229 cells, but not in SUM 149 cells. To determine if these in vitro cell line results would extrapolate to a real breast tumor situation, ERα- tumor specimens were obtained from the Tissue Procurement Core. Tumors were minced and divided evenly into a baseline sample and into tissue culture dishes containing medium alone, or supplemented with 10 μM U0126 or vehicle control DMSO. The minced tumor specimens in medium plus or minus U0126 were incubated at 37oC/5%CO2 for 20 hours. RNA was prepared from all treatment groups and analyzed for ERα mRNA level by qRT-PCR. Of the 12 tumors received to date, 6 displayed increased ERα mRNA levels after treatment with U0126. Collectively, these data are supportive of our hypothesis that there exists a population of ERα- tumors where upregulated growth factor signaling is directly involved in the generation of the ERα- phenotype by repressing ERα expression. Importanly, these data suggest that this reversible downregulation may be targeted clinically such that this repression can be reversed by inhibiting signaling through MAPK, resulting in re-expression of ERα and perhaps restoration of tamoxifen sensitivity.

Estrogen Regulation of Thrombospondin‐1 in Human Breast Cancer Cells

Regulation of Thrombospondin-1 by Natural and Synthetic Progestins in Human Breast Cancer Cells

Caveolin-1 Down-Regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 Beta-Estradiol-Stimulated Mammary Tumorigenesis

Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2

E2F-1 Directly Regulates Thrombospondin 1 Expression.

The Role of Thrombomodulin in Estrogen-Receptor-Positive Breast Cancer Progression, Metastasis, and Curcumin Sensitivity

Sphingosine Kinase Transmits Estrogen Signaling in Human Breast Cancer Cells.

Up-regulation of MMP-2 Expression by Estradiol via TGFβ1 in Prostate Stromal Cells

Sphingosine-1-phosphate Receptor 1 Transmits Estrogens’ Effects in Endothelial Cells

Tyrosine Phosphatase Shp2 Mediates The Estrogen Biological Action In Breast Cancer Via Interaction With The Estrogen Extranuclear Receptor

Exosomal Thrombospondin-1 Disrupts the Integrity of Endothelial Intercellular Junctions to Facilitate Breast Cancer Cell Metastasis

Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1

Estrogenic Down-Regulation of Protein Tyrosine Phosphatase Gamma (PTP Gamma) in Human Breast is Associated with Estrogen Receptor Alpha.

Involvement of Breast Epithelial-Stromal Interactions in the Regulation of Protein Tyrosine Phosphatase-Γ (ptpγ) Mrna Expression by Estrogenically Active Agents

Estrogen Enhances Tumor Growth and Angiogenesis Indirectly Via Mediation of Bone Marrow‑derived Cells As Well As Directly Through Stimulation of Tumor and Endothelial Cells.

Role of specificity protein transcription factors in estrogen-induced gene expression in MCF-7 breast cancer cells

Estrogen Regulation of Transferrin Gene Expression in MCF-7 Human Breast Cancer Cells

Human expression patterns: qualitative and quantitative analysis of thrombospondin‐1 under physiological and pathological conditions

Activation of Bone Morphogenetic Protein-6 Gene Transcription in MCF-7 Cells by Estrogen

Sphingosine Kinase (sphk) Mediates Transactivation of the Epidermal Growth Factor Receptor (egfr) by Estrogen in Breast Cancer Cells

Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.